Alvotech (ALVO) Competitors

Alvotech (NASDAQ:ALVO) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Which has more volatility and risk, ALVO or MRNA?

Alvotech has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500. Comparatively, Moderna has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Is ALVO or MRNA more profitable?

Moderna has a net margin of -110.04% compared to Alvotech's net margin of -123.47%. Alvotech's return on equity of 0.00% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-123.47%	N/A	-35.87%
Moderna	-110.04%	-28.74%	-21.83%

Which has higher valuation and earnings, ALVO or MRNA?

Alvotech has higher earnings, but lower revenue than Moderna. Alvotech is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$489.68M	5.29	-$551.73M	-$0.87	-9.89
Moderna	$3.20B	3.17	-$3.56B	-$9.28	-2.83

Does the media refer more to ALVO or MRNA?

In the previous week, Moderna had 16 more articles in the media than Alvotech. MarketBeat recorded 24 mentions for Moderna and 8 mentions for Alvotech. Moderna's average media sentiment score of 1.04 beat Alvotech's score of 0.05 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	15 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in ALVO or MRNA?

Moderna received 208 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 53.75% of users gave Moderna an outperform vote while only 50.00% of users gave Alvotech an outperform vote.

Company	Underperform	Outperform
Alvotech	Outperform Votes 7 50.00%	Underperform Votes 7 50.00%
Moderna	Outperform Votes 215 53.75%	Underperform Votes 185 46.25%

Do analysts recommend ALVO or MRNA?

Alvotech presently has a consensus target price of $18.00, suggesting a potential upside of 109.30%. Moderna has a consensus target price of $58.70, suggesting a potential upside of 123.70%. Given Moderna's higher probable upside, analysts plainly believe Moderna is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Moderna	4 Sell rating(s)	16 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04

Do institutionals & insiders believe in ALVO or MRNA?

75.3% of Moderna shares are held by institutional investors. 0.5% of Alvotech shares are held by company insiders. Comparatively, 11.0% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Moderna beats Alvotech on 14 of the 19 factors compared between the two stocks.